DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer

Information source: Soroka University Medical Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Locally Advanced Inoperable Non-small-lung Cancer

Intervention: Valproic acid (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Soroka University Medical Center

Official(s) and/or principal investigator(s):
Konstantin Lavrenkov, MD, PhD, Principal Investigator, Affiliation: Soroka University Medical Center

Overall contact:
Konstantin Lavrenkov, MD, PhD, Phone: 972-86400537, Email: constant@bgu.ac.il

Summary

This is non-randomized phase 2 study to evaluate toxicity and efficacy of VA with concurrent chemoradiotherapy (CCRT) containing weekly vinorelbine and cisplatin in patients with locally advanced inoperable non-small-cell lung cancer (NSCLC).All patients will be planned for three-dimensional conformal RT (3-DCRT). Concurrent weekly vinorelbine and cisplatin and oral valproic acid (VA)will be started at the first day of RT. Follow up will be conducted every 3 months after completion of the study treatment. Toxicity will be assessed using CTCAE, based on clinical examination and laboratory tests during the study treatment and at follow up visits. Response to treatment will be evaluated using RECIST criteria. Overall and progression free survival (OS and PFS) will be estimated using the Kaplan-Meier method.

Clinical Details

Official title: Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Vinorelbine and Cisplatin for Inoperable Locally Advanced Non-Small-Cell Lung Cancer

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Toxicity

Secondary outcome: Survival

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Age > 18 years. 2. Newly-diagnosed, histologically or cytologically confirmed NSCLC. 3. Inoperable stage IIIA-B disease 4. KPS > 60 5. FEV1 >1. 2L 6. No previous RT to chest 7. No serious comorbid condition 8. No treatment with biological response modifiers or cytotoxic agents within four weeks prior to study entry 9. No participation in clinical trial using any investigational drug or device within four weeks prior to study entry 10. No serious complication of malignant condition 11. No previous or concurrent malignancy at other sites except cone biopsied in situ carcinoma of the uterine cervix and adequately treated basal cell or squamous cell carcinoma of the skin 12. Adequate organ function as evidenced by the following peripheral blood counts or serum chemistries at study entry: Hemoglobin > 9. 0 Gm/dL WBC count > 4. 0x109/L Neutrophile count > 1. 5 cells x 109/L, Version 1, May 12, 2010 Platelet count > 100 x 109/L, Creatinine < 1. 5 mg/dL Total bilirubin < upper limit of normal (ULN) AST/SGOT < ULN Calcium < ULN 13. Ability to sign informed consent 14. Ability to attend follow-up visits Exclusion Criteria: 1. Operable disease 2. Metastases to contra-lateral mediastinal lymph nodes 3. Distant metastases 4. KPS < 60 5. FEV1 < 1. 2L 6. Previous RT to chest 7. Treatment with biological response modifiers or cytotoxic agents within four weeks prior to study entry 8. Participation in clinical trial using any investigational drug or device within four weeks prior to study entry 9. Major surgical procedure within two weeks prior to study entry 10. Serious comorbid condition, inclusive but not limited to myocardial infarction within previous six months, uncontrolled cardiac arrhythmias, uncontrolled angina pectoris, active infection including acute hepatitis 11. Serious complication of malignant condition 12. Previous or concurrent malignancy 13. Inadequate organ function as evidenced by the following peripheral blood counts or serum chemistries at study entry: Hemoglobin < 9. 0 Gm/dL WBC count < 4. 0x109/L Neutrophile count < 1. 5 cells x 109/L, Platelet count < 100 x 109/L, Creatinine > 1. 5 mg/dL Total bilirubin > ULN (upper limit of normal) AST/SGOT > ULN Version 1, May 12, 2010 Calcium > ULN 14. Inability to sign informed consent 15. Psychological, familial, sociological or geographical conditions which do not permit regular medical follow-up and compliance with the protocol

Locations and Contacts

Konstantin Lavrenkov, MD, PhD, Phone: 972-86400537, Email: constant@bgu.ac.il

Soroka University Medical Center, Beer Sheva 84101, Israel; Recruiting
Konstantin Lavrenkov, MD, PhD, Phone: +97286400537, Email: constant@bgu.ac.il
Julia Dudnik, MD, Phone: +97286400537, Email: juliad@clalit.org.il
Vladimir Gavrilov, MD, PhD, Sub-Investigator
Julia Dudnik, MD, Sub-Investigator
Kerenr Rouvinov, MD, Sub-Investigator
Additional Information

Starting date: February 2011
Last updated: March 27, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017